271 related articles for article (PubMed ID: 33444934)
1. Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.
Szeszko PR; McNamara RK; Gallego JA; Malhotra AK; Govindarajulu U; Peters BD; Robinson DG
Schizophr Res; 2021 Feb; 228():180-187. PubMed ID: 33444934
[TBL] [Abstract][Full Text] [Related]
2. A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.
Lyall AE; Nägele FL; Pasternak O; Gallego JA; Malhotra AK; McNamara RK; Kubicki M; Peters BD; Robinson DG; Szeszko PR
Psychiatry Res Neuroimaging; 2021 Jan; 307():111219. PubMed ID: 33221631
[TBL] [Abstract][Full Text] [Related]
3. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
[TBL] [Abstract][Full Text] [Related]
4. Association between serum long-chain omega-3 polyunsaturated fatty acids and cognitive performance in elderly men and women: The Kuopio Ischaemic Heart Disease Risk Factor Study.
D'Ascoli TA; Mursu J; Voutilainen S; Kauhanen J; Tuomainen TP; Virtanen JK
Eur J Clin Nutr; 2016 Aug; 70(8):970-5. PubMed ID: 27071510
[TBL] [Abstract][Full Text] [Related]
5. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers.
Buydens-Branchey L; Branchey M; Hibbeln JR
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):568-75. PubMed ID: 18060675
[TBL] [Abstract][Full Text] [Related]
6. Exploring the association between whole blood Omega-3 Index, DHA, EPA, DHA, AA and n-6 DPA, and depression and self-esteem in adolescents of lower general secondary education.
van der Wurff ISM; von Schacky C; Bergeland T; Leontjevas R; Zeegers MP; Kirschner PA; de Groot RHM
Eur J Nutr; 2019 Jun; 58(4):1429-1439. PubMed ID: 29549496
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols.
Cook CM; Hallaråker H; Sæbø PC; Innis SM; Kelley KM; Sanoshy KD; Berger A; Maki KC
Prostaglandins Leukot Essent Fatty Acids; 2016 Aug; 111():17-24. PubMed ID: 27151222
[TBL] [Abstract][Full Text] [Related]
8. Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y.
Thies F; Nebe-von-Caron G; Powell JR; Yaqoob P; Newsholme EA; Calder PC
Am J Clin Nutr; 2001 Mar; 73(3):539-48. PubMed ID: 11237929
[TBL] [Abstract][Full Text] [Related]
9. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
10. The impact of non-surgical periodontal treatment on serum levels of long chain-polyunsaturated fatty acids: a pilot randomized clinical trial.
Martinez GL; Koury JC; Brito F; Fischer RG; Gustafsson A; Figueredo CM
J Periodontal Res; 2014 Apr; 49(2):268-74. PubMed ID: 23721647
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial.
Chang JP; Chang SS; Chen HT; Chien YC; Yang HT; Huang SY; Tseng PT; Chang CH; Galecki P; Su KP
Brain Behav Immun; 2023 Aug; 112():125-131. PubMed ID: 37301235
[TBL] [Abstract][Full Text] [Related]
12. Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney RM; Steinmeyer BC; Freedland KE; Rubin EH; Rich MW; Harris WS
J Clin Psychiatry; 2016 Feb; 77(2):e138-43. PubMed ID: 26930527
[TBL] [Abstract][Full Text] [Related]
13. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
14. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis.
Amminger GP; Nelson B; Markulev C; Yuen HP; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; McGorry PD
Biol Psychiatry; 2020 Feb; 87(3):243-252. PubMed ID: 31690495
[TBL] [Abstract][Full Text] [Related]
15. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial.
Susai SR; Mongan D; Healy C; Cannon M; Nelson B; Markulev C; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; McGorry PD; Föcking M; Cotter D; Amminger GP
Brain Behav Immun; 2022 Jan; 99():147-156. PubMed ID: 34624483
[TBL] [Abstract][Full Text] [Related]
16. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial.
Dangour AD; Allen E; Elbourne D; Fasey N; Fletcher AE; Hardy P; Holder GE; Knight R; Letley L; Richards M; Uauy R
Am J Clin Nutr; 2010 Jun; 91(6):1725-32. PubMed ID: 20410089
[TBL] [Abstract][Full Text] [Related]
17. Fatty acids in plasma, white and red blood cells, and tissues after oral or intravenous administration of fish oil in rats.
Barros KV; Carvalho PO; Cassulino AP; Andrade I; West AL; Miles EA; Calder PC; Silveira VL
Clin Nutr; 2013 Dec; 32(6):993-8. PubMed ID: 23541913
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial.
Lin PY; Cheng C; Satyanarayanan SK; Chiu LT; Chien YC; Chuu CP; Lan TH; Su KP
Brain Behav Immun; 2022 Jan; 99():289-298. PubMed ID: 34755655
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
20. Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.
Markworth JF; Kaur G; Miller EG; Larsen AE; Sinclair AJ; Maddipati KR; Cameron-Smith D
FASEB J; 2016 Nov; 30(11):3714-3725. PubMed ID: 27461565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
